Market Spotlight: Thyroid Eye Disease (TED)
Market Spotlight: Thyroid Eye Disease (TED)
$1,318.00
Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Thyroid Eye Disease (TED) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Thyroid eye disease (TED) is associated with thyroid disease, and most commonly occurs in Graves’ disease, where it is estimated to be present in ~40% of patients.
- Epidemiological data are limited for TED, but it is reported in the literature that annual incidence in the general population is 16 per 100,000 in women and three per 100,000 in men.
- Based on these rates, Datamonitor Healthcare estimates that in 2022, there were 397,800 incident cases of TED worldwide, and expects that number to increase to 445,800 incident cases by 2030.
- The only approved drug in the TED space is Horizon’s Tepezza, which targets insulin-like growth factor-1 receptor. It is currently available as an intravenous formulation.
- There are only four industry-sponsored drugs in active clinical development for TED, with two drugs each in Phase I and Phase III.
- Therapies in development for TED target insulin-like growth factor-1 receptor. These drugs are being tested in oral, intravenous, and subcutaneous formulations.
- High-impact upcoming events for drugs in the TED space comprise topline results from the Chronic TED trial for Tepezza, and topline Phase III trial results for batoclimab, VRDN-001, and Tepezza.
- The overall likelihood of approval of a Phase I ophthalmology-other asset is 19%, and the average probability a drug advances from Phase III is 58.3%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for TED have been in the early and midphases of development, with 56% of trials in Phase I–II, and 44% in Phase III–IV.
- The US leads in terms of the number of TED clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
- Horizon Therapeutics has the highest number of ongoing clinical trials for TED, with four trials.
- Horizon Therapeutics leads industry sponsors with the highest overall number of clinical trials for TED
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Definition
7 Patient segmentation
9 Symptoms
9 Risk factors
10 Diagnosis
11 TREATMENT
11 Medical treatment
11 Orbital radiotherapy
11 Surgical treatment
13 EPIDEMIOLOGY
13 Thyroid eye disease occurrence in thyroid disorders
13 Incidence methodology
17 MARKETED DRUGS
19 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 VRDN-001 for Thyroid Eye Disease (August 15, 2022)
25 KEY UPCOMING EVENTS
26 PROBABILITY OF SUCCESS
27 LICENSING AND ASSET ACQUISITION DEALS
27 Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
27 CSPC Obtains Greater China Rights To Harbour BioMed’s Batoclimab
28 REVENUE OPPORTUNITY
29 CLINICAL TRIAL LANDSCAPE
30 Sponsors by status
31 Sponsors by phase
32 Recent events
34 BIBLIOGRAPHY
35 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in incident cases of thyroid eye disease, 2021–30
19 Figure 2: Overview of pipeline drugs for TED in the US
19 Figure 3: Pipeline drugs for TED, by company
19 Figure 4: Pipeline drugs for TED, by drug type
20 Figure 5: Pipeline drugs for TED, by classification
25 Figure 6: Key upcoming events in thyroid eye disease
26 Figure 7: Probability of success in the ophthalmology-other pipeline
29 Figure 8: Clinical trials in thyroid eye disease
29 Figure 9: Top 10 drugs for clinical trials in thyroid eye disease
30 Figure 10: Top 10 companies for clinical trials in thyroid eye disease
30 Figure 11: Trial locations in thyroid eye disease
31 Figure 12: Thyroid eye disease trials status
32 Figure 13: Thyroid eye disease trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalence of thyroid eye disease in Graves’ disease
14 Table 2: Incident cases of thyroid eye disease, 2021–30
18 Table 3: Marketed drugs for thyroid eye disease
21 Table 4: Pipeline drugs for TED in the US
23 Table 5: VRDN-001 for Thyroid Eye Disease (August 15, 2022)
28 Table 6: Historical global sales, by drug ($m), 2017–21
28 Table 7: Forecasted global sales, by drug ($m), 2023–27
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Obesity 
Sign up to the